THRB and metabolic dysfunction-associated steatohepatitis: Similarly, liver-specific thyroid hormone receptor (THR-β) agonists like resmetirom aim to target hepatic lipid metabolism in the treatment of MASLD and MASH, without influencing cardiovascular function.